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Abstract
Duchenne muscular dystrophy (DMD) is characterized by degeneration and atrophy of skeletal,
cardiac, and smooth muscles after a latent period of apparently normal development and
function. The gastrointestinal manifestations start in the second decade of life and are mainly
due to atrophy of smooth muscle layers. Refractory gastroparesis and chronic constipation can
lead to severe gastric and small bowel dilatation, which can be life threatening. Here, we
present a case of a 21-year-old male with a gigantic stomach secondary to DMD resolved with
conservative management and no surgical intervention.
Categories: Genetics, Internal Medicine, Gastroenterology
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Introduction
Duchenne muscular dystrophy (DMD) is characterized by degeneration and atrophy of skeletal,
cardiac, and smooth muscles after a latent period of apparently normal development and
function. The gastrointestinal manifestations start in the second decade of life and are mainly
due to atrophy of smooth muscle layers [1]. Gastrointestinal manifestations in DMD are not well
studied and can vary in severity. Refractory gastroparesis can lead to severe gastric and small
bowel dilatation. Chronic constipation can further compound the severity of gastric or small
bowel dilatation, which can be life threatening. The treatment of these manifestations is
mainly conservative with medical management and rarely requires surgery. Few case reports of
severe gastric and small bowel dilatation in DMD patients have been reported in the literature.
Here, we present a case of a 21-year-old male with gigantic stomach secondary to DMD
resolved with conservative management and no surgical intervention.
Case Presentation
A 21-year-old male with a past medical history of DMD, scoliosis with multiple back surgeries,
failure to thrive and atrial fibrillation presented with abdominal pain and vomiting for two
days. He was chronically constipated since the age of 15 years and had one to two bowel
movements per month with no use of laxatives. On admission, the patient was afebrile,
tachycardic with a heart rate of 148 beats per minute, hypotensive with a blood pressure of
89/55 mmHg, and tachypneic with a respiratory rate of 36/min. He was cachectic with severe
muscle wasting and had dry mucous membranes. His body mass index (BMI) was 14.8 kg/m2.
Physical exam showed a soft, non-tender, distended abdomen, with no guarding and rigidity.
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The patient presented with hypoactive bowel sounds and chronic muscle contractions in all the
four extremities. Laboratory values showed leukocytosis 20300/µL (normal 4000-10,000/µL)
with left shift (bands 22), hemoglobin 16.4 g/dL (normal 14-17 g/dL) and hematocrit 51.1%
(normal 41%-51%), blood urea nitrogen (BUN) 31 mg/dL (normal 8-20 mg/dL), creatinine 0.40
mg/dL (normal 0.7-1.3 mg/dL), mild elevation of aspartate aminotransferase (AST) 54 IU/L
(normal 40-35 U/L), prothrombin time (PT) 14s (normal 11-13 s), international normalized ratio
(INR) 1.3 (normal <1.1), partial thromboplastin time (PTT) 32.3 (normal 25-35 s) and normal
albumin 4.7 g/dL (normal 3.5-5.5 g/dL). He was severely intravascular volume-depleted as per
physical exam and laboratory values. He received aggressive fluid resuscitation with Ringer’s
lactate.
Computed tomography (CT) scan of the abdomen and pelvis with contrast showed massive
gastric distention with the stomach extending down to the low pelvis, and dilatation of the
proximal duodenum to the level of the midline/superior mesenteric artery (SMA) (Figures 1-3).
FIGURE 1: Computed tomography (CT) scan of the abdomen
(sagittal section) with contrast showing massively distended
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stomach extending into the pelvis
FIGURE 2: Computed tomography (CT) scan of the abdomen
(coronal section) with contrast showing massively distended
stomach extending into the pelvis
SMA: superior mesenteric artery.
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FIGURE 3: Computed tomography (CT) scan of the abdomen
(axial section) with contrast showing distended stomach with
distended duodenum to the level of SMA with narrow AMD <1
cm
SMA: superior mesenteric artery; AMD: aorto-mesenteric distance.
Since aorto-mesenteric distance (AMD) was less than 1 cm, a working diagnosis of SMA
syndrome was made. Upon placement of a nasogastric tube, three liters of gastric bilious
contents were evacuated. He was started on lactulose and was given a fleet of enemas with
manual disimpaction to help him have bowel movements. Esophagogastroduodenoscopy
showed ulcers in the anterior wall and greater curvature of the stomach body, with a normal
duodenal bulb and the second/third part of the duodenum. No strictures were visualized during
the procedure. CT angiography of the abdomen showed interval resolution of gastric and
duodenal distention, ruling out SMA syndrome. The patient’s gastric distention resolved with
conservative measures without any need of surgical intervention (Figure 4).
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FIGURE 4: Computed tomography (CT) scan of the abdomen
(axial section) with contrast showing resolution of gastric
distention with unchanged AMD <1 cm
SMA: superior mesenteric artery; AMD: aorto-mesenteric distance.
Discussion
Background
DMD is a progressive, X-linked recessive disorder with an incidence of approximately 30 per
100,000 live-born males. Patients can become symptomatic at 3-5 years of age and become fully
wheelchair dependent by 12 years of age [2]. DMD is caused by a mutation in the gene encoding
the protein dystrophin. This protein is an important part of the conduction system and affects
cell motility, shape, and transport [3-4]. Dystrophin is located on the inner surface of the
sarcolemma of muscle fibers and forms protein complexes with glycoproteins, which aid in
stabilization. In patients with DMD, this complex lacks dystrophin which leads to a weak
sarcolemma. Subsequently, muscle fibers undergo necrosis and are replaced by connective
tissue and fat, which can be visualized on muscle biopsy [2].
In patients with DMD, the gastrointestinal tract, which primarily consists of smooth muscle,
degenerates and atrophies while the connective tissue infiltrates [5]. Animal studies have
shown that dystrophin is present in the smooth muscle layers of the gastrointestinal tract of
control animals except for mice lacking full-length dystrophin and maintaining shorter
isoforms (mdx mice) [6]. Further studies have shown that mdx mice might have an existing
neuropathy in the myenteric neurons leading to gastrointestinal dysmotility of different
severity. This might be due to the increased size of synaptic vesicles and the number of
recycling vesicles in the myenteric neurons along with the lack of dystrophin protein
[7]. Disorders of gastric motility can result from a wide variety of causes and can be divided
into: disorders affecting the autonomic nervous system (diabetes, vagotomy), enteric nervous
system (visceral neuropathy), smooth muscle (DMD, scleroderma, amyloidosis, mitochondrial
cytopathy) and, possibly, abnormalities of the interstitial cells of Cajal (ICC). Our case falls into
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the category of smooth muscle disorders leading to the gastric hypo-motility. Very few case
reports of severe gastric and small bowel dilatation in DMD patients have been reported in the
literature. Crowe et al. described the first case of acute gastric dilatation in a 9-year-old boy
with DMD in 1961. This was followed by few other case reports by Robin and Falewski et al.
(1963), Stark et al. (1988), and Lunshof et al. (2000) [1,8-11].
Gastrointestinal manifestations
Gastrointestinal symptoms that manifest as a result of DMD have garnered more interest in
order to more optimally diagnose and treat. Many patients’ life spans do not reach adulthood,
leading to a lack of experience in treating adults with DMD. Since smooth muscle is located
throughout the gastrointestinal tract, its degeneration affects multiple organs. Dysphagia (36%
in 1 series) due to oropharyngeal dysfunction is one of the most predominant symptoms in
DMD patients [3]. Gastroparesis leading to gastrointestinal dilatation is another common
problem affecting these patients. Gastric emptying times in DMD patients, of various ages,
were shown to be significantly longer than their controls [12]. Barohn et al. showed that DMD
patients have delayed gastric-emptying times using radionuclide scintigraphy studies [13].
Severe gastroparesis can lead to severe gastric and small bowel dilatation. Impaired colonic
transit time, due to lack of ambulation, abdominal muscle weakness, and atrophy of smooth
muscle, might lead to high incidences of constipation in these patients [14]. Chronic
constipation can further compound the severity of gastric or small bowel dilatation, which can
be life threatening. Our patient also presented with this gastroparesis, which was evident by
vomiting and massively dilated stomach and small intestine, causing colonic compression. His
gastric dilatation was further worsened by his severe chronic constipation. Wheelchair-bound
patients can also present with gastro-esophageal reflux disease (GERD) and esophagitis due to
deterioration of the lower esophageal sphincter [15].
Treatment of gastrointestinal manifestations
The gastric manifestations in patients with DMD have been poorly understood and thus, under-
treated. This holds especially true in the adult population. Because DMD is a progressive
disease, adult patients have more extensive muscular deterioration and therefore present with
more severe symptoms. Proton pump inhibitors are effective, with few side effects in patients
with GERD and esophagitis. Constipation may be treated conservatively with increased fluid
and fiber intake or medically using stool softeners, laxatives, and fleet enemas [15]. Studies
have proven that pro-kinetics especially aid in treating neuropathic manifestations of DMD [4].
Gastric dilatation may be treated with nasogastric tube decompression, which if done in a
timely manner may help restore proper motility in acute cases [4,15]. If healthcare providers
become more aware of the existence of gastrointestinal manifestations in patients with DMD, a
more direct approach may be used for treatment, which could also be cost effective.
Ruling out other differential diagnoses
The severe gastric and small bowel dilatation in our patient reached the level of the SMA and
was found to have a narrowed AMD of less than 1 cm, leading to the inclusion of SMA
syndrome. Normal AMD is 1 to 2.8 cm [16]. However, taking into account the patient’s past
medical history, conservative measures including nasogastric decompression, stool softeners,
laxatives, fleet enemas, and manual disimpaction were performed with drastic resolution of
gastric distention on repeat imaging. There was no improvement in the AMD interval on the
repeat imaging, which ruled out SMA syndrome as a contributing factor towards the patient’s
massive gastric dilatation. The decreased AMD in our patient could have been due to loss of fat,
given his BMI was only 14.8 kg/m2.
Conclusions
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This was a unique case of acute gastric and small bowel dilatation, which is a rare
manifestation of DMD most likely secondary to gastroparesis. Our patient’s symptoms were due
to gastric and small bowel dilatation, which resolved with the conservative management with
no need of surgery. Based on our experience, internists should be further educated on
gastrointestinal manifestations in adult patients with DMD in order to improve outcomes, as it
is a rare entity encountered in adults due to the short lifespan of these patients.
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